NeuCyte
Latest round
- Series A
Last raised
- May 2018
Total raised
- $6.7M
Investors
- 2
About NeuCyte
NeuCyte, Inc.Founded in 2015, NeuCyte, Inc. operates out of Sunnyvale, US, and specializes in biotechnology solutions for CNS drug discovery. The company was established to develop human induced pluripotent stem cell (iPSC)-derived neurons for research applications. Daniel Haag is noted as the founder, while Tao Huang serves as the CEO.NeuCyte, Inc. specializes in innovative biotechnology solutions aimed at advancing central nervous system (CNS) drug discovery. The company’s core offering is its proprietary SynFire® technology, which enables the generation of human induced pluripotent stem cell (iPSC)-derived neurons. This technology facilitates the creation of highly functional in vitro platforms for various applications including target identification and validation, efficacy testing, neurotoxicity assessment, and disease modeling. NeuCyte’s platforms utilize patient-derived and genetically engineered neural cell types to develop unique cell-based assays that model neurological and neurodegenerative disorders such as Alzheimer's disease, ALS, Epilepsy, and Fragile X Syndrome.ORG to pursue research initiatives. Key offerings, including the SynFire® platform and associated assay services, are positioned to attract clients in the pharmaceutical industry, enhancing their drug development pipelines through advanced in vitro models.NeuCyte, Inc.7 mn from May 2018 to enhance its product offerings and market reach. The company is focused on developing new products utilizing its SynFire® technology, with plans for upcoming launches in the near future. Additionally, NeuCyte targets expansion into new markets, particularly in Europe and Asia, with a timeline to establish a stronger presence by 2023.
Who invested in NeuCyte
2 investors across 1 round
See all investors in NeuCyte
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 8, 2018
Amount
$6.7M
Investors
Questions about NeuCyte
Who invested in NeuCyte?
NeuCyte has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has NeuCyte raised?
NeuCyte has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did NeuCyte last raise money?
NeuCyte's most recent round on record is a Series A, in May 2018.
What does NeuCyte do?
NeuCyte is a pharmaceuticals company.
Where is NeuCyte headquartered?
NeuCyte is headquartered in Sunnyvale, US.
Which VCs invest in companies like NeuCyte?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at NeuCyte's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like NeuCyte? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.